CN119546643A - 5t4结合剂及其用途 - Google Patents
5t4结合剂及其用途 Download PDFInfo
- Publication number
- CN119546643A CN119546643A CN202380053588.4A CN202380053588A CN119546643A CN 119546643 A CN119546643 A CN 119546643A CN 202380053588 A CN202380053588 A CN 202380053588A CN 119546643 A CN119546643 A CN 119546643A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510753500.0A CN120607619A (zh) | 2022-05-13 | 2023-05-10 | 5t4结合剂及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341944P | 2022-05-13 | 2022-05-13 | |
| US63/341,944 | 2022-05-13 | ||
| PCT/US2023/066819 WO2023220626A2 (en) | 2022-05-13 | 2023-05-10 | 5t4 binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510753500.0A Division CN120607619A (zh) | 2022-05-13 | 2023-05-10 | 5t4结合剂及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119546643A true CN119546643A (zh) | 2025-02-28 |
Family
ID=88731098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380053588.4A Pending CN119546643A (zh) | 2022-05-13 | 2023-05-10 | 5t4结合剂及其用途 |
| CN202510753500.0A Pending CN120607619A (zh) | 2022-05-13 | 2023-05-10 | 5t4结合剂及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510753500.0A Pending CN120607619A (zh) | 2022-05-13 | 2023-05-10 | 5t4结合剂及其用途 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025180472A1 (zh) * | 2024-02-28 | 2025-09-04 | 惠和生物技术(上海)有限公司 | 单克隆抗体分子及其用途 |
| WO2026010986A1 (en) * | 2024-07-05 | 2026-01-08 | Solve Therapeutics, Inc. | 5t4-binding proteins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170091A1 (en) * | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| WO2016034666A1 (en) * | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| KR20220030934A (ko) * | 2019-05-31 | 2022-03-11 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 항-gal9 면역-억제 결합 분자 |
-
2023
- 2023-05-10 TW TW112117412A patent/TW202400639A/zh unknown
- 2023-05-10 WO PCT/US2023/066819 patent/WO2023220626A2/en not_active Ceased
- 2023-05-10 IL IL316788A patent/IL316788A/en unknown
- 2023-05-10 CN CN202380053588.4A patent/CN119546643A/zh active Pending
- 2023-05-10 AU AU2023267764A patent/AU2023267764A1/en active Pending
- 2023-05-10 KR KR1020247040741A patent/KR20250024530A/ko active Pending
- 2023-05-10 PE PE2024002518A patent/PE20251275A1/es unknown
- 2023-05-10 CN CN202510753500.0A patent/CN120607619A/zh active Pending
- 2023-05-10 JP JP2024566539A patent/JP2025518493A/ja active Pending
- 2023-05-10 CA CA3252305A patent/CA3252305A1/en active Pending
- 2023-05-10 CR CR20240489A patent/CR20240489A/es unknown
- 2023-05-10 US US18/863,565 patent/US20250326858A1/en active Pending
- 2023-05-10 EP EP23804474.7A patent/EP4522660A4/en active Pending
-
2024
- 2024-11-08 MX MX2024013871A patent/MX2024013871A/es unknown
- 2024-11-11 DO DO2024000234A patent/DOP2024000234A/es unknown
- 2024-11-11 CL CL2024003442A patent/CL2024003442A1/es unknown
- 2024-11-12 CO CONC2024/0015383A patent/CO2024015383A2/es unknown
-
2025
- 2025-08-26 CL CL2025002572A patent/CL2025002572A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20251275A1 (es) | 2025-05-14 |
| JP2025518493A (ja) | 2025-06-17 |
| EP4522660A4 (en) | 2026-04-29 |
| WO2023220626A2 (en) | 2023-11-16 |
| CL2025002572A1 (es) | 2025-10-03 |
| WO2023220626A3 (en) | 2023-12-14 |
| CA3252305A1 (en) | 2023-11-16 |
| KR20250024530A (ko) | 2025-02-18 |
| CN120607619A (zh) | 2025-09-09 |
| TW202400639A (zh) | 2024-01-01 |
| DOP2024000234A (es) | 2025-02-28 |
| US20250326858A1 (en) | 2025-10-23 |
| MX2024013871A (es) | 2024-12-06 |
| EP4522660A2 (en) | 2025-03-19 |
| CL2024003442A1 (es) | 2025-02-28 |
| CO2024015383A2 (es) | 2025-02-04 |
| CR20240489A (es) | 2025-01-07 |
| AU2023267764A1 (en) | 2024-11-21 |
| IL316788A (en) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102794369B1 (ko) | 이중특이 항체 및 그의 용도 | |
| US20250197502A1 (en) | Multispecific binding agents and uses thereof | |
| JP7840312B2 (ja) | 多重特異性結合性作用剤およびその使用 | |
| CN116410318A (zh) | 抗axl拮抗抗体 | |
| JP2019030313A (ja) | ヒトox40受容体に対する結合分子 | |
| JP7627258B2 (ja) | 抗bcma抗体、その抗原結合断片、及びそれらの医療用途 | |
| US20250326858A1 (en) | 5t4 binding agents and uses thereof | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| JP7854423B2 (ja) | Pd-l1結合性作用剤およびその使用 | |
| TWI889766B (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| CN118974098A (zh) | 多重特异性结合剂及其用途 | |
| WO2025230866A1 (en) | Anti-alpha5 integrin antibodies and uses thereof | |
| CN121843961A (zh) | 可活化的ror结合剂和其用途 | |
| CN117503951A (zh) | 一种抗体药物偶联物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |